Charles River (CRL) Advances in T-Cell Therapy With New Alliance

More on the News Industry Prospect In June 2024, Charles River announced a collaboration with MatTek Corporation to develop a New Approach Methodology inhalation toxicology test to reduce reliance on traditional animal research methods. The program will be funded through 1.3 million grant. Charles River currently carries a Zacks Rank #3 (Hold). The Inogen stock has surged 32.4% year to date. In the past 60 days, the bottom-line estimate for 2024 has narrowed from a loss of 2.56 per share to a loss of $2.4 ...